Krebs Biochemicals & Industries reported a standalone net loss of ₹2.48 crore for the quarter ended June 2026, representing a significant improvement from the net loss of ₹5.32 crore recorded in the corresponding quarter of the previous financial year. According to reports from Business Standard, this marks a 53% reduction in losses year-on-year for the company.
The company demonstrated strong revenue growth with sales rising 27.37% to ₹6.98 crore in Q1 FY27 compared to ₹5.48 crore in the same quarter of the previous financial year. As reported by Business Standard, this revenue expansion indicates improved business operations and market demand for the company's products.
The company's operating profit margin (OPM) improved significantly to 11.89% in Q1 FY27 from a negative 37.96% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this substantial improvement in operational efficiency contributed to the overall reduction in net losses despite the company still reporting a net loss position.
PBDT (Profit Before Depreciation and Tax) improved by 76% to -₹0.89 crore from -₹3.72 crore in the previous year's corresponding quarter. As reported by Business Standard, the company's PBT (Profit Before Tax) also showed improvement, reducing by 53% to -₹2.48 crore from -₹5.32 crore in Q1 FY26. These metrics indicate better cost management and operational efficiency despite the company still reporting losses at the net level.
